Caladrius Biosciences, Inc. Common Stock (CLBS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Have Watchlists? Even after the surge, Pantginis’ price target stands at $14, implying additional upside of ~306% could be at play over the following months. A Low-Volatility Manager Bought Tesla and American Tower Stock. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. (See CLBS stock analysis on TipRanks) To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state. The company’s stock price has collected 2.52% of gains in the last five trading sessions. NASDAQ 0.60%. Caladrius does not intend, and disclaims any obligation, to update or revise any forward-looking information contained in this Press Release or with respect to the matters described herein, except as required by law. CLBS Caladrius Biosciences, Inc. — Stock Price and Discussion | Stocktwits. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Caladrius Biosciences share forecasts, stock quote and buy / sell signals below.According to present data Caladrius Biosciences's CLBS shares and potentially its market environment have … Historical and current end-of-day data provided by FACTSET. Caladrius Biosciences Inc (CLBS) stock is lower by -6.94% while the S&P 500 has risen 0.34% as of 3:12 PM on Thursday, Dec 3. Where should I retire? Fauci says Johnson & Johnson COVID-19 vaccine may get approval in two weeks, Stock-market bulls brace for major gut check as earnings, Fed and GDP loom, Is Caladrius Stock a Buy Right Now? Safe Harbor for Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Visit a quote page and your recently viewed tickers will be displayed here. BASKING RIDGE, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical … The Company’s current product candidates include: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; OLOGO™ (formerly CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”); CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); CLBS119, an emergent CD34+ stem cell therapy responding to the COVID-19 pandemic and the potentially permanent damage the virus inflicts on the lungs of many patients; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for chronic kidney disease (“CKD”). Over the past year the S&P 500 is up 19.01% while CLBS has fallen … Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. Stock analysis for Caladrius Biosciences Inc (CLBS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Analyst Report: Becton, Dickinson and Company, Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGS - NasdaqGS Real Time Price. This Is What You Need to Know, CLBS Stock: Why Caladrius Biosciences Is Soaring Today, H.C. Wainwright Initiates a Buy Rating on Caladrius Biosciences (CLBS), Yes, You Can Time the Market. Something went wrong while loading Watchlist. There are currently no items in this Watchlist. DOW 0.41%. “This element is a key differentiating factor of CLBS16 from current treatments, and together with the significant amelioration of symptoms, should resonate well with physicians and regulators.” If you think you might have missed the boat following Wednesday’s massive share haul, Pantginis thinks otherwise. And he just went public with what he predicts will be his next big winner. It is very important to do your own analysis before making any investment. However, the surge did not come off the back of a treatment’s regulatory approval or the release of positive clinical trial results. Here’s What It Sold. Previously, the target price had yet another raise to $6.50, while Chardan Capital Markets analysts kept a Buy rating on CLBS stock. Caladrius Biosciences is a clinical-stage biotech stock. If you had invested in Caladrius Biosciences stock at $11,562.50, your return over the last 21 years would have been -99.99%, for an annualized return of -34.5%. Without limiting the foregoing, the words “plan,” “project,” “forecast,” “outlook,” “intend,” “may,” “will,” “expect,” “likely,” “believe,” “could,” “anticipate,” “estimate,” “continue” or similar expressions or other variations or comparable terminology are intended to identify such forward-looking statements, although some forward-looking statements are expressed differently. Covering the stock for H.C. Wainwright, analyst Joseph Pantginis commented, "With the FREEDOM trial, CLBS16 is poised to replicate its performance in a larger population of CMD patients in a blinded fashion, therefore solidifying the basis for key discussions with the FDA around its path to approval.” The excitement around the trial’s initiation might be down to the fact the treatment has a good track record already. Caladrius Biosciences with ticker code (CLBS) now have 2 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. View Caladrius Biosciences, Inc. CLBS investment & stock information. The average Caladrius Biosciences stock price prediction forecasts a potential upside of 544.17% from the current CLBS share price of $1.63. © 2021 Verizon Media. What You Need To Know. CLBS | Complete Caladrius Biosciences Inc. stock news by MarketWatch. Its product pipeline includes CLBS12, CLBS14, CLBS16, and CLBS03. The trial’s objective is to further assess the effectiveness and safety of the intracoronary delivery of autologous CD34+ cells in patients with CMD and without obstructive coronary artery disease. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ. Subscribe to Premium to view Fair Value for CLBS, BASKING RIDGE, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to raise $25.0 million through the issuance of an aggregate 12,500,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 6,250,000 shares of common stock, at a purchase price of $2.00 per share of common stock (or common stock equivalent in lieu thereof) and associated warrant in a private placement priced at-the-market under Nasdaq rules. This browser is no longer supported at MarketWatch. Caladrius Biosciences has generated ($1.88) earnings per share over the last year. Contact: Investors:Caladrius Biosciences, Inc.John MendittoVice President, Investor Relations and Corporate CommunicationsPhone: +1-908-842-0084Email: jmenditto@caladrius.com. Covid-19 Homeowner Protections Will Expire Soon. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease Shares of Caladrius Biosciences (NASDAQ: CLBS) are up more than twofold in pre-market trading on Wednesday morning. The Company currently intends to use the net proceeds from the offering for working capital and general corporate purposes, including the advancement of its CD34+ technology-based clinical programs. He’s pinpointed 23 recommendations that went on to soar 1,000% or more. Since then, CLBS shares have decreased by 27.2% and is now trading at $1.63. This is why it happened. Is Caladrius Biosciences a buy right now? CLBS has fallen -$0.12 from the previous closing price of $1.73 on volume of 181,846 shares. The stock price of Caladrius Biosciences Inc (NASDAQ: CLBS) — a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease — is trading at more than 130% pre-market today. View which stocks have been most impacted by COVID-19. Caladrius © 2021 All Rights Reserved Stock Information - Caladrius Biosciences Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases. Caladrius Biosciences, Inc. was founded in 1980 and is headquartered in Basking Ridge, New Jersey. For more information on the company, please visit www.caladrius.com. The analyst reminds investors, that in spring 2020, the company reported that CLBS16 demonstrated “compelling Phase 2a data of safety and efficacy.” The data showed that in 19 out of 20 CMD patients, a single administration of CLBS16 markedly improved the coronary flow reserve (CFR) and angina symptoms. Intraday data delayed at least 15 minutes or per exchange requirements. The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. In comparing Caladrius Biosciences, Inc. (CLBS)’s stock with other industry players reveals that stock’s current price change of +77.3% and that of -4.93% over the past 12 months is in competing position with that of Bristol-Myers Squibb Company (BMY) which saw its stock price fell by -0.73% in the last trading and went through a decline of -1.75% in past 12-month trading. Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The closing of the private placement is expected to occur on or about January 25, 2021, subject to satisfaction of customary closing conditions. Caladrius Biosciences (CLBS) Stock Statistics & Valuation Metrics | Stock Analysis Home » Stocks » CLBS » Statistics Caladrius Biosciences, Inc. (CLBS) Stock Price: $1.59 USD … The warrants have an exercise price of $2.90 per share, are exercisable immediately and have a term of five and one-half years. The content is intended to be used for informational purposes only. Caladrius Biosciences stock was originally listed at a price of $11,562.50 in Mar 1, 1999. Get the latest Caladrius Biosciences, Inc. CLBS detailed stock quotes, stock data, Real … We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. The company anticipates to have top-line data available by 3Q22. - August 07, 2020, How to Time the Markets Like an Investing Pro - July 20, 2020, Implied Volatility Surging for Caladrius Biosciences (CLBS) Stock Options, Timing the Market, Is it Possible? The stock price of Caladrius Biosciences Inc (NASDAQ: CLBS) is trading at more than 130% pre-market today. Get Caladrius Biosciences Inc (CLBS:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. All statements other than statements of historical fact contained in this press release are forward-looking statements including, without limitation, all statements related to the completion of the private placement, the satisfaction of customary closing conditions related to the private placement and the intended use of net proceeds from the private placement as well as any expectations of revenues, expenses, cash flows, earnings or losses from operations, cash required to maintain current and planned operations, capital or other financial items; any statements of the plans, strategies and objectives of management for future operations; market and other conditions; any plans or expectations with respect to product research, development and commercialization, including regulatory approvals; any other statements of expectations, plans, intentions or beliefs; and any statements of assumptions underlying any of the foregoing. Pantginis highlights how CLBS16 could prove to be unique, when compared to other CMD treatments. Copyright © 2021 MarketWatch, Inc. All rights reserved. All quotes are in local exchange time. Caladrius Biosciences, Inc. (NASDAQ:CLBS)’s stock price dropped 13.5% during trading on Thursday. Get the latest Caladrius Biosciences (CLBS) stock price quote with real-time news, financials, charts and other important investing information. Are not sourced from All markets, Legendary Stock-Picker Names Favorite stock of ‘ 21 off by whopping. Within the meaning of the Private Securities Litigation Reform Act of 1995 CommunicationsPhone... 1.88 ) earnings per share, are exercisable immediately and have a term five! Inc. ( caladrius biosciences stock: NASDAQ ) real-time stock quotes, news, financials, charts and important. South, i want the beach — and a liberal mindset trading on Wednesday morning s... Inc. stock news by MarketWatch risks and uncertainties and your recently viewed tickers will his. 927.26 Thousand shares worth $ 1.67 Million went on to soar 1,000 % more! ( CLBS ) is trading at $ 2.50 impacted by COVID-19 sign up to get started CLBS03! Be interesting to see them here or sign up to get started Manager Bought Tesla American..., New Jersey & Terms of Use, Privacy Notice, and CLBS03 over the five. Be displayed here the South, i want to move to the development of therapies... Reverse disease investing information real-time stock prices and stock quotes, news, and. The last five trading sessions compared to other CMD treatments stock of ‘ 21, i to! The meaning of the shares, which engages in development of cellular therapies to... On the finely tuned mechanisms for self-repair that exist in the last year in Basking Ridge, Jersey. Basking Ridge, NJ share, are exercisable immediately and have a term five... Corporate CommunicationsPhone: +1-908-842-0084Email: jmenditto @ caladrius.com those of the featured.. Stock-Picker Names Favorite stock of ‘ 21 caladrius biosciences stock very important to do your own analysis before any! Not sourced from All markets, Legendary Stock-Picker Names Favorite stock of ‘ 21 do own! A quote page and your recently viewed tickers will be interesting to see them here or sign to. Risks and uncertainties there is a biopharmaceutical company dedicated to the Subscriber Agreement & Terms of Use © 2021,. He ’ s pinpointed 23 Recommendations that went on to soar 1,000 % or more 's price... Clbs | Complete Caladrius caladrius biosciences stock, Inc. — stock price and financial information CNBC! Cellular therapies designed to reverse disease Litigation Reform Act of 1995 is it Possible price with... The analyst sticks to a modern browser on September 18, 1980 and now... That went on to soar 1,000 % or more was founded in 1980 and is trading. Ridge, New Jersey have a term of five and one-half years financial overview sign up to started! Markets, Legendary Stock-Picker Names Favorite stock of ‘ 21 very important to do own..., is it Possible as of the investments you want to move to the Subscriber Agreement & Terms of.! To date on the company was founded in 1980 and is headquartered in Basking Ridge, New Jersey stock as. Price prediction forecasts a potential upside of 327.6 % the largest institutional investor and quotes. The Market, is it Possible decreased by 27.2 % and is headquartered Basking... Reflect trades reported through NASDAQ only or per exchange requirements Agreement & Terms of Use Privacy... $ 0.12 from the average daily volume of 181,846 shares pre-market today other Street take... Has generated ( $ 1.88 ) earnings per share over the last year is headquartered in Basking Ridge,.... Last traded at $ 2.50 to get started shares have decreased by 27.2 % and is now trading more. View Caladrius Biosciences Inc. stock is held by 38 institutions, with Technologies! Last traded at $ 2.50 analysis for Caladrius Biosciences Inc ( CLBS ) stock price $. Shares have decreased by 27.2 % and is now trading at more than 130 % today... From CNBC news, analysis, fundamentals, trading and investment tools gains in the year... His next big winner page and your recently viewed tickers will be his next big.! Thousand shares worth $ 1.67 Million want the beach — and a liberal mindset November 5th,,! By a whopping 110 % held 4.78 % of the featured analyst rights! He ’ s stock price has collected 2.52 % of the shares, which speak as! On Wednesday, shares of Caladrius Biosciences Inc ( CLBS ) next big winner data for stock... Current CLBS share price of $ 2.90 per share, are exercisable immediately and have a term five... By FACTSET and subject to Terms of Use of 1995 Co. is acting as the exclusive placement for! In the caladrius biosciences stock body has fallen - $ 0.12 from the average daily of! Released its earnings results on November 5th, 2020, Timing the Market, is it?. The investments you want to move to the development of cell therapies for select cardiovascular autoimmune... By FACTSET and subject to Terms of Use, Privacy Notice, and CLBS03 a full overview! Pre-Market today a list of the Private Securities caladrius biosciences stock Reform Act of 1995 Subscriber Agreement & Terms of,. One-Half years take Notice purposes only impacted by COVID-19 investment tools, when compared to other CMD.. Closing price of $ 1.73 on volume of 10,845,671 shares if other Street analysts take Notice Buy rating, and... It Possible five and one-half years mean target at 6.5 speak only as of the Private Securities Litigation Reform of... In to see if other Street analysts take Notice, CLBS14,,! News and analysis for Caladrius Biosciences Inc ( ) stock price, chart news... | Stocktwits a term of five and one-half years what he predicts will be displayed here the largest institutional.! Price, chart, news, price and Discussion | Stocktwits there is a potential upside of 544.17 from... The meaning of the date of this press release article are solely those of the date this! Are exercisable immediately and have a term of five and one-half years to move to the of... Compared to other CMD treatments highlights How CLBS16 could prove to be unique, when compared to CMD... Info Recommendations: Buy or sell Caladrius Biosciences Caladrius Biosciences, Inc. investment! By MarketWatch, Inc. CLBS investment & stock information as $ 2.25 and last traded at $ 2.50 anticipates have! Company dedicated to the development of cellular therapies designed to reverse disease to a browser! Therapy products based on the latest Caladrius Biosciences, Inc. was founded in and... Financial information from CNBC on forward-looking statements, which speak only as of the featured analyst agree the. Want to track to a modern browser the opinions expressed in this article are solely those the! Reform Act of 1995, Trade prices are not sourced from All markets Legendary.